Navigation Links
Ranbaxy Secures Final FDA Approval for Quinapril Hydrochloride + Hydrochlorothiazide Tablets
Date:3/5/2009

PRINCETON, N.J., March 5 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received approval from the U.S. Food and Drug Administration to manufacture and market Quinapril Hydrochloride & Hydrochlorothiazide (Quinapril + HCTZ) Tablets, 10mg/12.5mg, 20mg/12.5mg and 20mg/25mg. The Application for the drug was submitted by Ranbaxy, from its Ohm Laboratories manufacturing facility located in North Brunswick, New Jersey. The Office of Generic Drugs, U.S. Food and Drug Administration, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Accuretic(R) Tablets of Pfizer Pharmaceuticals Ltd. Total annual market sales for Quinapril + HCTZ Tablets were $29 million (IMS - MAT: December 2008).

According to Jim Meehan, Vice President of Sales and Distribution for RPI, "We are pleased to receive this final approval for Quinapril + HCTZ, an ACE inhibitor that is used to treat high blood pressure. This is the second ANDA approval granted by the FDA, to Ranbaxy, in the last two months. Product will be made available to all classes of trade in the near term."

Ohm, based in North Brunswick, New Jersey, is a wholly owned subsidiary of Ranbaxy Laboratories Limited. Ohm is engaged in the sale and distribution of generic and branded private label, OTC products in the U.S. healthcare system.

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.

Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quali
'/>"/>

SOURCE Ranbaxy Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Press Statement Issued by Ranbaxy Laboratories Limited
2. Cipher Pharmaceuticals announces U.S. distribution and supply agreement with Ranbaxy for CIP-ISOTRETINOIN
3. Ranbaxy and Pfizer Settle Lipitor Litigation Worldwide
4. Ranbaxy to Bring in Daiichi Sankyo as Majority Partner; Strategic Combination Creates Innovator and Generic Pharma Powerhouse
5. Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Oral Solution
6. Ranbaxy Gains Approval to Manufacture and Market Cefuroxime Axetil for Oral Suspension
7. Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Tablets (OTC), 5mg and 10mg
8. Ranbaxy Receives Tentative Approval For Valsartan Tablets
9. Ranbaxy First to Gain Approval to Manufacture and Market Clarithromycin for Oral Suspension, USP
10. Ranbaxy Gains Approval to Manufacture and Market Carvedilol Tablets in the U.S. Market
11. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:DecisionView Launches StudyOptimizer(TM) 4 2DecisionView Launches StudyOptimizer(TM) 4 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 2AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 3Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 4558 1Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 4558 2Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 4558 3Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 4558 4Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 4558 5StayWell Custom Communications Announces Strategic Alliance with Siteimprove 48133 1StayWell Custom Communications Announces Strategic Alliance with Siteimprove 48133 2StayWell Custom Communications Announces Strategic Alliance with Siteimprove 48133 3StayWell Custom Communications Announces Strategic Alliance with Siteimprove 48133 4National Marrowthon Campaign Aims to Bring Nearly 50 000 to the Be The Match Registry 28SM 29 in Two Weeks 48131 1National Marrowthon Campaign Aims to Bring Nearly 50 000 to the Be The Match Registry 28SM 29 in Two Weeks 48131 2National Marrowthon Campaign Aims to Bring Nearly 50 000 to the Be The Match Registry 28SM 29 in Two Weeks 48131 3National Marrowthon Campaign Aims to Bring Nearly 50 000 to the Be The Match Registry 28SM 29 in Two Weeks 48131 4